title: Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.
abstract: Many studies have demonstrated that the long-term, virological, immunological and clinical effectiveness of highly active antiretroviral therapy (HAART) is mainly related to durable suppression of viral replication. Among the specific antiretroviral agents available today, nelfinavir has been widely used in the last 3 years. This open label, non comparative, retrospective study on 307 patients living with HIV aimed to evaluate the effectiveness of an antiretroviral (ART) regimen including nelfinavir as first-line HAART in terms of rate and durability of viro-immunological response. Most patients, 258/307 (84%), were pre-treated whereas only 49/307 (16%) were treatment naive. The median baseline CD4 cell count was 223 cells/mm3 for naive patients and 317 cells/mm3 for experienced patients whereas median HIV RNA values were 2,500 and 82,000 copies/ml for experienced and naive patients respectively. Median times spent on nelfinavir were 839 and 897 days for experienced and naive patients respectively, with 171/258 pre-treated patients (66%) remaining on nelfinavir-based therapy up to 24 months. Overall, the mean CD4 increase was 196 cells/mm3 with a relevant increment of 165 in experienced patients and 367 cells/mm3 in naive patients (p<0.01). The mean viral load variation in naive patients was -2.22 log10 and in experienced patients -0.53 log10 (p<0.01). In conclusion, nelfinavir, as part of HAART, demonstrated long-term benefit (almost two-thirds of patients stayed on nelfinavir up to 24 months). The response rate in patients naive to antiretroviral therapy was better than for experienced patients. Although there were some differences related to the baseline CD4 level, the overall response rate was good, supporting the role of nelfinavir in HAART.
authors.affiliation: Department of Infectious Diseases, IRCCS Ospedale S Raffaele, Vita e Salute University, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Castagna
authors.forename: A
authors.initials: A
authors.lastname: Danise
authors.forename: B
authors.initials: B
authors.lastname: Giudici
authors.forename: A
authors.initials: A
authors.lastname: Lazzarin
authors.forename: F
authors.initials: F
authors.lastname: Castelli
authors.forename: G
authors.initials: G
authors.lastname: Paraninfo
authors.forename: G
authors.initials: G
authors.lastname: Carosi
authors.forename: P L
authors.initials: PL
authors.lastname: Carriero
mesh_terms: D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007558:Italy; D019888:Nelfinavir / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019888:Nelfinavir